EUVIMEDEUVIMED entdecken
Crossref

Discovery of Tetrahydropyrazolopyrazine Derivatives as Potent and Selective MYT1 Inhibitors for the Treatment of Cancer

Yazhou Wang, Chao Wang, Tingting Liu, Hongyun Qi, Shan Chen, Xin Cai, Man Zhang, Alex Aliper iD, Feng Ren iD, Xiao Ding iD, Alex Zhavoronkov iD

Journal of Medicinal Chemistry · 11.01.2024 · 67 (1) · 420-432

DOI: 10.1021/acs.jmedchem.3c01476 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 26.12.2023. Verfasst von Yazhou Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Insilico Medicine Shanghai Ltd, Suite 901, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast and gynecological cancers are among the leading causes of death in women worldwide, illustrating the urgent need for innovative treatment options. We identified MYT1 as a promising new therapeutic target for breast and gynecological cancer using PandaOmics, an AI-driven target discovery platform. The synthetic lethal relationship of MYT1 in tumor cell lines with CCNE1 amplification enhanced this rationale. Through structure-based drug design, we developed a series of novel, potent, and highly selective inhibitors specifically targeting MYT1. Importantly, our lead compound, featuring a tetrahydropyrazolopyrazine ring, exhibits remarkable selectivity over WEE1, a related kinase associated with bone marrow suppression upon inhibition. Optimization of potency and physical properties resulted in the discovery of compound 21, a novel MYT1 inhibitor, exhibiting optimal pharmacokinetic properties and promising in vivo antitumor efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsFemaleHumansCell Line, TumorBreastDrug DesignProtein Kinase InhibitorsCell ProliferationDNA-Binding ProteinsTranscription Factors

Substanzen

Protein Kinase InhibitorsAntineoplastic AgentsMYT1 protein, humanDNA-Binding ProteinsTranscription Factors

Autor:innen und Institutionen

  • Insilico Medicine Shanghai Ltd, Suite 901, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China.
  • Insilico Medicine AI Limited, Masdar City 145748, Abu Dhabi, United Arab Emirates.

ORCID-Profile: Alex Aliper, Feng Ren, Xiao Ding, Alex Zhavoronkov

Zitieren

APA

Wang, Y., Wang, C., Liu, T., Qi, H., Chen, S., Cai, X., Zhang, M., Aliper, A., Ren, F., Ding, X., & Zhavoronkov, A. (2024). Discovery of Tetrahydropyrazolopyrazine Derivatives as Potent and Selective MYT1 Inhibitors for the Treatment of Cancer. Journal of Medicinal Chemistry, 67(1), 420-432. https://doi.org/10.1021/acs.jmedchem.3c01476

Vancouver

Wang Y, Wang C, Liu T, Qi H, Chen S, Cai X, et al. Discovery of Tetrahydropyrazolopyrazine Derivatives as Potent and Selective MYT1 Inhibitors for the Treatment of Cancer. Journal of Medicinal Chemistry. 2024;67(1):420-432. doi:10.1021/acs.jmedchem.3c01476

BibTeX
@article{Wang2024,
  author = {Wang, Yazhou and Wang, Chao and Liu, Tingting and Qi, Hongyun and Chen, Shan and Cai, Xin and Zhang, Man and Aliper, Alex and Ren, Feng and Ding, Xiao and Zhavoronkov, Alex},
  title = {Discovery of Tetrahydropyrazolopyrazine Derivatives as Potent and Selective MYT1 Inhibitors for the Treatment of Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {1},
  pages = {420--432},
  doi = {10.1021/acs.jmedchem.3c01476}
}
Kostenlos starten →